Pilot study of low-dose interleukin-11 in patients with bone marrow failure

R. Kurzrock, J. Cortes, D. A. Thomas, S. Jeha, S. Pilat, M. Talpaz

Research output: Contribution to journalArticle

Abstract

Purpose: Interleukin-11 (IL-11) is a thrombopoietic cytokine that attenuates postchemotherapy thrombocytopenia at doses of 50 μg/kg/d subcutaneously. Very little is known about the activity of IL-11 in patients with bone marrow failure states. Patients and Methods: Our preliminary experience with IL-11 at doses of 50 μg/kg/d suggested that patients with bone marrow failure developed significant peripheral and pulmonary edema after the prolonged dosing necessary for treating these conditions. We, therefore, initiated a study of low-dose IL-11 (starting dose, 10 μg/kg/d). Results: Sixteen patients were assessable for response. Six patients had diploid cytogenetics; the others had a variety of chromosomal abnormalities. Six (38%) of 16 patients showed a platelet response to IL-11, and two had a multilineage response (to IL-11 alone, n = 1; to IL-11 plus G-CSF and erythropoietin, n = 1). The median increase in peak platelet counts was 95 x 109/L above baseline in the responders (range, increase of 55 x 109/L to 130 x 109/L above baseline). Responders included five of 11 patients with myelodysplasia and one of four patients with aplastic anemia. Response durations were 12, 13, 14+, 25, 30, and 30+ weeks. Side effects of IL-11 were mild (peripheral edema, n = 7; conjunctival injection, n = 7; myalgia, n = 1; all grade 1). Seven patients had no side effects. Conclusion: Our pilot study suggests that administration of low-dose IL-11 (10 μg/kg/d) can raise platelet counts without significant toxicity in selected thrombocytopenic patients with bone marrow failure.

Original languageEnglish (US)
Pages (from-to)4165-4172
Number of pages8
JournalJournal of Clinical Oncology
Volume19
Issue number21
DOIs
StatePublished - Nov 1 2001
Externally publishedYes

Fingerprint

Interleukin-11
Bone Marrow
Platelet Count
Aplastic Anemia
Myalgia
Granulocyte Colony-Stimulating Factor
Pulmonary Edema
Erythropoietin
Diploidy
Cytogenetics
Chromosome Aberrations
Thrombocytopenia
Interleukin-10
Edema
Blood Platelets

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Pilot study of low-dose interleukin-11 in patients with bone marrow failure. / Kurzrock, R.; Cortes, J.; Thomas, D. A.; Jeha, S.; Pilat, S.; Talpaz, M.

In: Journal of Clinical Oncology, Vol. 19, No. 21, 01.11.2001, p. 4165-4172.

Research output: Contribution to journalArticle

Kurzrock, R. ; Cortes, J. ; Thomas, D. A. ; Jeha, S. ; Pilat, S. ; Talpaz, M. / Pilot study of low-dose interleukin-11 in patients with bone marrow failure. In: Journal of Clinical Oncology. 2001 ; Vol. 19, No. 21. pp. 4165-4172.
@article{d5e9e6e89aff4f9fa990e7641b408506,
title = "Pilot study of low-dose interleukin-11 in patients with bone marrow failure",
abstract = "Purpose: Interleukin-11 (IL-11) is a thrombopoietic cytokine that attenuates postchemotherapy thrombocytopenia at doses of 50 μg/kg/d subcutaneously. Very little is known about the activity of IL-11 in patients with bone marrow failure states. Patients and Methods: Our preliminary experience with IL-11 at doses of 50 μg/kg/d suggested that patients with bone marrow failure developed significant peripheral and pulmonary edema after the prolonged dosing necessary for treating these conditions. We, therefore, initiated a study of low-dose IL-11 (starting dose, 10 μg/kg/d). Results: Sixteen patients were assessable for response. Six patients had diploid cytogenetics; the others had a variety of chromosomal abnormalities. Six (38{\%}) of 16 patients showed a platelet response to IL-11, and two had a multilineage response (to IL-11 alone, n = 1; to IL-11 plus G-CSF and erythropoietin, n = 1). The median increase in peak platelet counts was 95 x 109/L above baseline in the responders (range, increase of 55 x 109/L to 130 x 109/L above baseline). Responders included five of 11 patients with myelodysplasia and one of four patients with aplastic anemia. Response durations were 12, 13, 14+, 25, 30, and 30+ weeks. Side effects of IL-11 were mild (peripheral edema, n = 7; conjunctival injection, n = 7; myalgia, n = 1; all grade 1). Seven patients had no side effects. Conclusion: Our pilot study suggests that administration of low-dose IL-11 (10 μg/kg/d) can raise platelet counts without significant toxicity in selected thrombocytopenic patients with bone marrow failure.",
author = "R. Kurzrock and J. Cortes and Thomas, {D. A.} and S. Jeha and S. Pilat and M. Talpaz",
year = "2001",
month = "11",
day = "1",
doi = "10.1200/JCO.2001.19.21.4165",
language = "English (US)",
volume = "19",
pages = "4165--4172",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "21",

}

TY - JOUR

T1 - Pilot study of low-dose interleukin-11 in patients with bone marrow failure

AU - Kurzrock, R.

AU - Cortes, J.

AU - Thomas, D. A.

AU - Jeha, S.

AU - Pilat, S.

AU - Talpaz, M.

PY - 2001/11/1

Y1 - 2001/11/1

N2 - Purpose: Interleukin-11 (IL-11) is a thrombopoietic cytokine that attenuates postchemotherapy thrombocytopenia at doses of 50 μg/kg/d subcutaneously. Very little is known about the activity of IL-11 in patients with bone marrow failure states. Patients and Methods: Our preliminary experience with IL-11 at doses of 50 μg/kg/d suggested that patients with bone marrow failure developed significant peripheral and pulmonary edema after the prolonged dosing necessary for treating these conditions. We, therefore, initiated a study of low-dose IL-11 (starting dose, 10 μg/kg/d). Results: Sixteen patients were assessable for response. Six patients had diploid cytogenetics; the others had a variety of chromosomal abnormalities. Six (38%) of 16 patients showed a platelet response to IL-11, and two had a multilineage response (to IL-11 alone, n = 1; to IL-11 plus G-CSF and erythropoietin, n = 1). The median increase in peak platelet counts was 95 x 109/L above baseline in the responders (range, increase of 55 x 109/L to 130 x 109/L above baseline). Responders included five of 11 patients with myelodysplasia and one of four patients with aplastic anemia. Response durations were 12, 13, 14+, 25, 30, and 30+ weeks. Side effects of IL-11 were mild (peripheral edema, n = 7; conjunctival injection, n = 7; myalgia, n = 1; all grade 1). Seven patients had no side effects. Conclusion: Our pilot study suggests that administration of low-dose IL-11 (10 μg/kg/d) can raise platelet counts without significant toxicity in selected thrombocytopenic patients with bone marrow failure.

AB - Purpose: Interleukin-11 (IL-11) is a thrombopoietic cytokine that attenuates postchemotherapy thrombocytopenia at doses of 50 μg/kg/d subcutaneously. Very little is known about the activity of IL-11 in patients with bone marrow failure states. Patients and Methods: Our preliminary experience with IL-11 at doses of 50 μg/kg/d suggested that patients with bone marrow failure developed significant peripheral and pulmonary edema after the prolonged dosing necessary for treating these conditions. We, therefore, initiated a study of low-dose IL-11 (starting dose, 10 μg/kg/d). Results: Sixteen patients were assessable for response. Six patients had diploid cytogenetics; the others had a variety of chromosomal abnormalities. Six (38%) of 16 patients showed a platelet response to IL-11, and two had a multilineage response (to IL-11 alone, n = 1; to IL-11 plus G-CSF and erythropoietin, n = 1). The median increase in peak platelet counts was 95 x 109/L above baseline in the responders (range, increase of 55 x 109/L to 130 x 109/L above baseline). Responders included five of 11 patients with myelodysplasia and one of four patients with aplastic anemia. Response durations were 12, 13, 14+, 25, 30, and 30+ weeks. Side effects of IL-11 were mild (peripheral edema, n = 7; conjunctival injection, n = 7; myalgia, n = 1; all grade 1). Seven patients had no side effects. Conclusion: Our pilot study suggests that administration of low-dose IL-11 (10 μg/kg/d) can raise platelet counts without significant toxicity in selected thrombocytopenic patients with bone marrow failure.

UR - http://www.scopus.com/inward/record.url?scp=0035503148&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035503148&partnerID=8YFLogxK

U2 - 10.1200/JCO.2001.19.21.4165

DO - 10.1200/JCO.2001.19.21.4165

M3 - Article

C2 - 11689585

AN - SCOPUS:0035503148

VL - 19

SP - 4165

EP - 4172

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 21

ER -